API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
2X-121 (stenoparib) is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and Tankyrase 1 and 2. It is being evaluated for the treatment of advanced recurrent ovarian cancer.
Lead Product(s): Stenoparib
Therapeutic Area: Oncology Product Name: 2X-121
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2024
Details:
2X-121 (stenoparib) is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and Tankyrase 1 and 2. It is being evaluated for the treatment of advanced recurrent ovarian cancer.
Lead Product(s): Stenoparib
Therapeutic Area: Oncology Product Name: 2X-121
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2023
Details:
2X-121 (stenoparib) is a PARP inhibitor in Phase 2 development for ovarian cancer and in Phase 1 development for advanced solid tumors in a combination treatment with dovitinib, a pan-tyrosine kinase inhibitor that has previously been developed through Phase 3 in renal cancer.
Lead Product(s): Stenoparib
Therapeutic Area: Oncology Product Name: 2X-121
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2023
Details:
Stenoparib is a dual-targeted inhibitor of PARP 1, 2 and tankyrase 1, 2 where dovitinib is a pan-tyrosine kinase inhibitor. The combination may increase the chances of cancer apoptosis and providing synergistic, enhanced antitumor activity.
Lead Product(s): Dovitinib,Stenoparib
Therapeutic Area: Oncology Product Name: TKI258
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2023
Details:
The DRP® platform has proven its ability to provide a statistically significant prediction of clinical outcome from drug treatment in cancer patients in 37 out of 47 clinical studies that were examined including ongoing, prospective Phase 2 trials of Stenoparib and IXEMPRA®.
Lead Product(s): Dovitinib,Stenoparib
Therapeutic Area: Oncology Product Name: TKI258
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 02, 2022
Details:
The additional pre-clinical results show that stenoparib demonstrated antiviral activity inhibiting the delta variant in a dose-dependent manner in Vero E6 cells. The delta variant used for the experiments carries an additional deletion in ORF7a, a rapidly spreading mutation.
Lead Product(s): Stenoparib
Therapeutic Area: Infections and Infectious Diseases Product Name: 2X-121
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Viroclinics Biosciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2021
Details:
Currently, the delta variant (lineage B.1.617.2) has become the dominant strain of SARS-CoV-2, and near-term tests of stenoparib against this variant are being initiated by Allarity.
Lead Product(s): Stenoparib
Therapeutic Area: Infections and Infectious Diseases Product Name: 2X-121
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 05, 2021
Details:
The current and planned in-vitro studies, focusing on SARS-CoV-2 lineage B.1.1.7 and B.1.351, follow previous positive pre-clinical test results with stenoparib as a treatment of SARS-CoV-2 published in the peer-review journal mBio.
Lead Product(s): Stenoparib
Therapeutic Area: Infections and Infectious Diseases Product Name: 2X-121
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 24, 2021
Details:
Based on the previous positive pre-clinical test results with stenoparib as a treatment of SARS-CoV-2, Allarity Therapeutics will now test the similar ability of stenoparib to block the infection and replication of SARS-CoV-2 lineage B.1.1.7.
Lead Product(s): Stenoparib
Therapeutic Area: Infections and Infectious Diseases Product Name: 2X-121
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 26, 2021
Details:
Allarity holds global, exclusive rights to the PARP inhibitor, Stenoparib, under an existing license with Eisai, in the field of cancer therapeutics and treatment. With the amendment, Allarity now further holds global, exclusive rights to the drug as an anti-viral therapy.
Lead Product(s): Stenoparib
Therapeutic Area: Infections and Infectious Diseases Product Name: 2X-121
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Allarity Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 14, 2020
Details:
Oncology Venture plans to advance Stenoparib into human clinical trials as a potential therapy for COVID-19. Stenoparib (2X-121) is a novel small molecule, targeted inhibitor of Poly ADP-Ribose Polymerase, a key DNA damage repair enzyme active in cancer cells.
Lead Product(s): Stenoparib
Therapeutic Area: Infections and Infectious Diseases Product Name: 2X-121
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 26, 2020
Details:
The Company now has 100 % ownership of 2X-121, which is being clinically developed as an anti-cancer therapeutic, as well as being tested as an anti-viral agent against COVID-19.
Lead Product(s): Stenoparib
Therapeutic Area: Oncology Product Name: 2X-121
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: 2X Oncology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition July 13, 2020
Details:
Oncology Venture will test the ability of 2X-121 to block the infection of cells and replication of carnivorous in pre-clinical Studies at Pathogen & Microbiome Institute.
Lead Product(s): Stenoparib
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Oncology Venture
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 22, 2020